Personal Finance

Here's Why Avadel Pharmaceuticals Dropped as Much as 13.3% Today

A finger tracing a candle chart showing losses on a digital screen.

What happened

Shares of pharma specialist Avadel Pharmaceuticals (NASDAQ: AVDL) sank over 13% Wednesday after the company announced a massive debt offering of $125 million in senior notes bearing a 4.5% interest rate and due date in 2023. The company expects net proceeds of about $119.6 million, or up to $137.7 million if additional debt notes are purchased, from the offering.

Avadel Pharmaceuticals has a market cap of just $360 million following the move, so it's easy to see that Mr. Market isn't thrilled with the company taking on about one-third of its valuation in debt. Plus, it will go along with an existing $60 million in long-term debt.

As of 2:03 p.m. EST, the stock had settled to an 11.2% loss.

A finger tracing a candle chart showing losses on a digital screen.

Image source: Getty Images.

So what

The debt offering comes as Avadel Pharmaceuticals is retooling its business to focus on urology, sleep, and hospital-focused products. Just days ago the company announced it was selling its pediatric segment to Cerecor and entering into an agreement with the buyer to continue developing certain products. That helps put things in perspective as the extra cash will no doubt be put to use developing products and expanding its presence in those core markets.

It's also worth noting that Avadel Pharmaceuticals has a relatively robust business. In the first nine months of 2017 it generated $138 million in revenue, which marked a 29% increase from the year-ago period. The business produced $76 million in net income during that span, compared to a net loss of $46 million in the prior-year period -- although both totals were dramatically influenced by non-cash charges related to the fair value of certain assets.

Now what

Wednesday's massive senior debt offering isn't an ideal development. However, the Irish pharma is no slouch. The company appears capable of putting the low interest rate cash to good use and, more importantly, repaying it on time. The stock's recent volatility isn't something investors should take lightly, but prices near 52-week lows could signal an opportunity for long-term investors.

10 stocks we like better than Avadel Pharmaceuticals plc

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now… and Avadel Pharmaceuticals plc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 5, 2018

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More